| Joseph O Gilg, MD | |
|
8421 Plum Dr, Des Moines, IA 50322-7356 | |
| (515) 643-9699 | |
| (515) 643-9698 |
| Full Name | Joseph O Gilg |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 37 Years |
| Location | 8421 Plum Dr, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205941416 | NPI | - | NPPES |
| 0097840 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 29131 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone Des Moines Medical Center | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Arthritis And Osteoporosis Center Pc | 0941514715 | 17 |
News Archive
While many scientists and pharmaceutical companies are racing to develop a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, there is also an urgent need for a coronavirus disease (COVID-19) treatment. The potent virus has now spread to 210 countries and territories, affecting more than 3.04 million people. Now, a team of German scientists is working on using antibodies to prevent and treat COVID-19.
Trevor Dyson-Hudson, MD, director of the Center for Spinal Cord Injury Research at Kessler Foundation, was awarded a $549,000 grant by the New Jersey Commission on Spinal Cord Research.
Researchers from the University of Bristol, Oxford Brookes University and the University of California San Diego neatly demonstrated how the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits high affinity for nicotinic acetylcholine receptors (nAChRs), with significant implications for coronavirus disease (COVID-19) pathology and infectivity. Their findings are published on the bioRxiv* preprint server.
Alcohol consumption has been identified as a modifiable risk factor for cancers such as gastric cancer. A new report in the The American Journal of Pathology sheds light on how specific proteins interact with alcohol, and how that interplay impacts survival and response to platinum-based adjuvant chemotherapy in patients with gastric cancer who may or may not still be drinking.
Bioengineers from University of California, San Diego are developing new regenerative therapies for heart disease. The work could influence the way in which regenerative therapies for cardiovascular and other diseases are treated in the future.
› Verified 6 days ago
| Entity Name | Iowa Arthritis And Osteoporosis Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720462914 PECOS PAC ID: 0941514715 Enrollment ID: O20150806012531 |
News Archive
While many scientists and pharmaceutical companies are racing to develop a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, there is also an urgent need for a coronavirus disease (COVID-19) treatment. The potent virus has now spread to 210 countries and territories, affecting more than 3.04 million people. Now, a team of German scientists is working on using antibodies to prevent and treat COVID-19.
Trevor Dyson-Hudson, MD, director of the Center for Spinal Cord Injury Research at Kessler Foundation, was awarded a $549,000 grant by the New Jersey Commission on Spinal Cord Research.
Researchers from the University of Bristol, Oxford Brookes University and the University of California San Diego neatly demonstrated how the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits high affinity for nicotinic acetylcholine receptors (nAChRs), with significant implications for coronavirus disease (COVID-19) pathology and infectivity. Their findings are published on the bioRxiv* preprint server.
Alcohol consumption has been identified as a modifiable risk factor for cancers such as gastric cancer. A new report in the The American Journal of Pathology sheds light on how specific proteins interact with alcohol, and how that interplay impacts survival and response to platinum-based adjuvant chemotherapy in patients with gastric cancer who may or may not still be drinking.
Bioengineers from University of California, San Diego are developing new regenerative therapies for heart disease. The work could influence the way in which regenerative therapies for cardiovascular and other diseases are treated in the future.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph O Gilg, MD 8421 Plum Dr, Urbandale, IA 50322-7356 Ph: (515) 270-7222 | Joseph O Gilg, MD 8421 Plum Dr, Des Moines, IA 50322-7356 Ph: (515) 643-9699 |
News Archive
While many scientists and pharmaceutical companies are racing to develop a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, there is also an urgent need for a coronavirus disease (COVID-19) treatment. The potent virus has now spread to 210 countries and territories, affecting more than 3.04 million people. Now, a team of German scientists is working on using antibodies to prevent and treat COVID-19.
Trevor Dyson-Hudson, MD, director of the Center for Spinal Cord Injury Research at Kessler Foundation, was awarded a $549,000 grant by the New Jersey Commission on Spinal Cord Research.
Researchers from the University of Bristol, Oxford Brookes University and the University of California San Diego neatly demonstrated how the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits high affinity for nicotinic acetylcholine receptors (nAChRs), with significant implications for coronavirus disease (COVID-19) pathology and infectivity. Their findings are published on the bioRxiv* preprint server.
Alcohol consumption has been identified as a modifiable risk factor for cancers such as gastric cancer. A new report in the The American Journal of Pathology sheds light on how specific proteins interact with alcohol, and how that interplay impacts survival and response to platinum-based adjuvant chemotherapy in patients with gastric cancer who may or may not still be drinking.
Bioengineers from University of California, San Diego are developing new regenerative therapies for heart disease. The work could influence the way in which regenerative therapies for cardiovascular and other diseases are treated in the future.
› Verified 6 days ago
Dr. Joshua C Lukenbill, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant Street, Suite 100, Des Moines, IA 50309 Phone: 515-282-2921 Fax: 515-282-1035 | |
Dr. Akshay Mahesh Khatri, M.B.B.S., MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant St Ste 300, Des Moines, IA 50309 Phone: 515-241-4200 Fax: 515-241-4048 | |
Ravinder Dervesh, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 411 Laurel St Ste 1225, Des Moines, IA 50314 Phone: 515-633-3770 Fax: 515-288-6713 | |
Mr. David Augusto Terrero Salcedo, M.D Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant St Ste 300, Des Moines, IA 50309 Phone: 515-241-4200 Fax: 515-241-4048 | |
Tyler Mumm, DO Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-2261 Fax: 515-643-5802 | |
Bilal Hasan Baig, DO Rheumatology Medicare: Medicare Enrolled Practice Location: 1200 Pleasant St, Des Moines, IA 50309 Phone: 515-241-6636 Fax: 515-241-4080 | |
Dr. Sean D Cunningham, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1215 Pleasant St, Ste 206, Des Moines, IA 50309 Phone: 515-875-9092 Fax: 515-875-9828 |